November 4, 2015 SOURCE:  REGEN BIOPHARMA INC.

Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy.  Company Intends to Utilize NR2F6 Gene-Silenced Immune Cells to Amplify Body’s Own Anti-Tumor Defenses.

October 13, 2015 SOURCE: REGEN BIOPHARMA INC.

Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President.   Dr. Lander was the former assistant provost of Weill Cornell Medical College at Cornell University and research chief at Sidra Medical and Research Center (Qatar)